Portal de Periódicos da CAPES

Experience with Glycoprotein IIb/IIIa Antagonists in Patients with Acute Coronary Syndromes

2002; Wiley; Volume: 15; Issue: 2 Linguagem: Inglês

10.1111/j.1540-8183.2002.tb01044.x

1540-8183

David E. Kandzari, Kenneth W. Mahaffey,

Heparin-Induced Thrombocytopenia and Thrombosis

Journal of Interventional CardiologyVolume 15, Issue 2 p. 121-129 Free to Read Experience with Glycoprotein IIb/IIIa Antagonists in Patients with Acute Coronary Syndromes DAVID E. KANDZARI M.D., Corresponding Author DAVID E. KANDZARI M.D. Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina Box 31203, Duke University Medical Center, Durham, NC 27710. Fax: (919) 668–7058; e-mail: [email protected]Search for more papers by this authorKENNETH W. MAHAFFEY M.D., KENNETH W. MAHAFFEY M.D. Duke Clinical Research Institute, Duke University Medical Center, Durham, North CarolinaSearch for more papers by this author DAVID E. KANDZARI M.D., Corresponding Author DAVID E. KANDZARI M.D. Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina Box 31203, Duke University Medical Center, Durham, NC 27710. Fax: (919) 668–7058; e-mail: [email protected]Search for more papers by this authorKENNETH W. MAHAFFEY M.D., KENNETH W. MAHAFFEY M.D. Duke Clinical Research Institute, Duke University Medical Center, Durham, North CarolinaSearch for more papers by this author First published: 02 July 2007 https://doi.org/10.1111/j.1540-8183.2002.tb01044.xCitations: 1AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Braunwald E, Jones RH, Mark DB, et al. Diagnosing and managing unstable angina. Circulation 1994; 90: 613–622. 10.1161/01.CIR.90.1.613 CASPubMedWeb of Science®Google Scholar 2 Cairns J, Theroux P, Armstrong P, et al. Unstable angina: Report from a Canadian expert roundtable. Can J Cardiol 1996; 12: 1279–1292. CASPubMedWeb of Science®Google Scholar 3 The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Results of the TIMI IIIB trial. Circulation 1994; 89: 1545–1556. 10.1161/01.CIR.89.4.1545 PubMedWeb of Science®Google Scholar 4 The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335: 775–782. 10.1056/NEJM199609123351103 PubMedWeb of Science®Google Scholar 5 The Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy—I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81–106. Google Scholar 6 The CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–1339. 10.1016/S0140-6736(96)09457-3 CASPubMedGoogle Scholar 7 Pepine CJ. Aspirin and newer orally active antiplatelet agents in the treatment of the post-myocardial infarction patient. J Am Coll Cardiol 1998; 32: 1126–1128. CASPubMedWeb of Science®Google Scholar 8 The CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502. 10.1056/NEJMoa010746 CASPubMedWeb of Science®Google Scholar 9 Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndrome. N Engl J Med 1992; 326: 242–250.310–318. 10.1056/NEJM199201233260406 CASPubMedWeb of Science®Google Scholar 10 Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553–1559. 10.1056/NEJM199506083322306 CASPubMedWeb of Science®Google Scholar 11 Phillips DR, Charo IF, Parisi LV, et al. The platelet membrane glycoprotein IIb/IIIa complex. Blood 1988; 71: 831–843. CASPubMedWeb of Science®Google Scholar 12 Pytela R, Pierschbacher MD, Ginsberg MH, et al. Platelet membrane glycoprotein IIb/IIIa: Member of a family of Arg-Gly-Asp specific adhesion receptors. Science 1986; 231: 1559–1562. 10.1126/science.2420006 CASPubMedWeb of Science®Google Scholar 13 Coller B, Peerschke EI, Scudder LE, et al. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983; 72: 325–338. 10.1172/JCI110973 CASPubMedWeb of Science®Google Scholar 14 Adgey JAA. Overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Am Heart J 1998; 135(Suppl.): S43–S55. 10.1016/S0002-8703(98)70297-2 CASPubMedWeb of Science®Google Scholar 15 The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956–961. 10.1056/NEJM199404073301402 PubMedWeb of Science®Google Scholar 16 The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689–1696. 10.1056/NEJM199706123362401 PubMedWeb of Science®Google Scholar 17 The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997; 349: 1429–1435. 10.1016/S0140-6736(96)10452-9 PubMedWeb of Science®Google Scholar 18 The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997; 349: 1422–1428. 10.1016/S0140-6736(96)10172-0 PubMedGoogle Scholar 19 The RESTORE Study Group. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445–1453. 10.1161/01.CIR.96.5.1445 PubMedGoogle Scholar 20 Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998; 98: 2829–2835. 10.1161/01.CIR.98.25.2829 CASPubMedWeb of Science®Google Scholar 21 The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998; 352: 87–92. 10.1016/S0140-6736(98)06113-3 PubMedWeb of Science®Google Scholar 22 The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy.): A randomised, placebo-controlled trial. Lancet 2000; 356: 2037–2044. 10.1016/S0140-6736(00)03400-0 PubMedWeb of Science®Google Scholar 23 O'Shea JC, Hafley GE, Greenberg S, et al., For the ESPRIT Investigators. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. The ESPRIT trial: A randomized controlled trial. JAMA 2001; 285: 2468–2473. 10.1001/jama.285.19.2468 CASPubMedWeb of Science®Google Scholar 24 Tcheng JE, For the ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) 1-year results. Presented at: the Paris Course on Revascularization; 2001 May; Paris, France. Google Scholar 25 Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998; 98: 734–741. 10.1161/01.CIR.98.8.734 CASPubMedWeb of Science®Google Scholar 26 Montalescot G, Barragan P, Wittenberg O, et al., For the ADMIRAL Investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344: 1895–1903. 10.1056/NEJM200106213442503 CASPubMedWeb of Science®Google Scholar 27 Ferguson JJ. Meeting highlights: Highlights of the 72nd Scientific Sessions of the American Heart Association. Circulation 2000; 102: e1–e5. 10.1161/01.CIR.102.1.e1 CASPubMedGoogle Scholar 28 Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344: 1888–1894. 10.1056/NEJM200106213442502 CASPubMedWeb of Science®Google Scholar 29 Madan M, Berkowitz SD, Tcheng JE. Glycoprotein IIb/IIIa integrin blockade. Circulation 1998; 98: 2629–2635. 10.1161/01.CIR.98.23.2629 CASPubMedWeb of Science®Google Scholar 30 Berkowitz SD, Harrington RA, Rund MM, et al. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1997; 96: 3810. PubMedWeb of Science®Google Scholar 31 Bednar B, Bednar RA, Cook JJ, et al. Drug-dependent antibodies against GP IIb/IIIa induced thrombocytopenia. Circulation 1996; 94(Suppl. I): I–99. Google Scholar 32 Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994; 90: 1757–1764. 10.1161/01.CIR.90.4.1757 PubMedWeb of Science®Google Scholar 33 The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498–1505. 10.1056/NEJM199805213382103 PubMedGoogle Scholar 34 Ferguson JJ. Meeting highlights: Highlights of the 21st Congress of the European Society of Cardiology. Circulation 1999; 100: e126–e131. 10.1161/01.CIR.100.25.e126 CASPubMedWeb of Science®Google Scholar 35 The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488–1497. 10.1056/NEJM199805213382102 PubMedGoogle Scholar 36 The PARAGON Investigators. An international, randomized, controlled trial of lamifiban, a platelet glycoprotein IIb/IIIa inhibitor, heparin, or both in unstable angina. Circulation 1998; 97: 2386–2395. 10.1161/01.CIR.97.24.2386 PubMedWeb of Science®Google Scholar 37 Theroux P, Kouz S, Roy L, et al. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: The Canadian lamifiban study. Circulation 1996; 94: 899–905. 10.1161/01.CIR.94.5.899 CASPubMedWeb of Science®Google Scholar 38 Moliterno DJ. Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: Rationale and design of the PARAGON B study. The PARAGON B International Steering Committee. Am Heart J 2000; 139: 563–566. 10.1016/S0002-8703(00)90031-0 CASPubMedWeb of Science®Google Scholar 39 Villareal RP, Kim P, Mahmood H, et al. Meeting highlights: Highlights of the 49th Scientific Sessions of the American College of Cardiology. Circulation 2000; 102: e53–e60. 10.1161/01.CIR.102.9.e53 PubMedGoogle Scholar 40 The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Study Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436–443. 10.1056/NEJM199808133390704 PubMedGoogle Scholar 41 Schulman SP, Goldschmidt PJ, Topol EJ, et al. Effects of integrilin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina: A randomized multicenter trial. Circulation 1996; 94: 2083–2089. 10.1161/01.CIR.94.9.2083 CASPubMedWeb of Science®Google Scholar 42 The GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: The GUSTO-IV ACS randomised trial. Lancet 2001; 357: 1915–1924. 10.1016/S0140-6736(00)05060-1 CASPubMedWeb of Science®Google Scholar 43 Harrington RA. A randomized comparison of the platelet inhibitory profiles of abciximab, tirofiban and eptifibatide: The COMPARE study, (personal communication). Google Scholar 44 Cannon CP, Weintraub WS, Demopoulos L, et al. Comparison of invasive versus conservative strategy in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban: The Treat Angina with Aggrastat and Determine the Cost of Therapy with an Invasive of Conservative Strategy (TACTICS-TIMI 18) Investigators. N Eng J Med 2001; 344: 1879–1887. 10.1056/NEJM200106213442501 CASPubMedWeb of Science®Google Scholar 45 Roe MT, Harrington RA, Prosper DM, et al., For the PURSUIT Investigators. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease. Circulation 2000; 102: 1101–1106. 10.1161/01.CIR.102.10.1101 CASPubMedWeb of Science®Google Scholar 46 Gold HK, Coller BS, Yasuda T, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GP IIb/IIIa antibody in a canine preparation. Circulation 1988; 77: 670–677. 10.1161/01.CIR.77.3.670 CASPubMedWeb of Science®Google Scholar 47 Yasuda T, Gold HK, Fallon JT, et al. Monoclonal antibody against platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest 1988; 81: 1284–1291. 10.1172/JCI113446 CASPubMedWeb of Science®Google Scholar 48 Gold HK, Garabedian HD, Dinsmore RE, et al. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators: Observations in animals and humans. Circulation 1997; 95: 1755–1759. 10.1161/01.CIR.95.7.1755 CASPubMedWeb of Science®Google Scholar 49 Ohman EM, Kleiman NS, Gacioch G, et al., For the IMPACT-AMI Investigators. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction: Results of a randomized; placebo-controlled, dose-ranging trial. Circulation 1997; 95: 846–854. 10.1161/01.CIR.95.4.846 CASPubMedWeb of Science®Google Scholar 50 Nicolini FA, Lee P, Rios G, et al. Combination of platelet fibrinogen receptor antagonist and direct antithrombin inhibitor at low doses markedly improves thrombolysis. Circulation 1994; 89: 1902–1909. 10.1161/01.CIR.89.4.1802 Google Scholar 51 Harrington RA. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: Results of the platelet aggregation receptor antagonist dose investigation and reperfusion gain in myocardial infarction (PARADIGM) trial. J Am Coll Cardiol 1998; 32: 2003–2010. 10.1016/S0735-1097(98)00474-4 PubMedWeb of Science®Google Scholar 52 Amman EM, Giugliano RP, McCabe CH, et al., For the TIMI-14 Investigators. Abciximab (ReoPro) potentiates thrombolysis in ST elevation myocardial infarction: Results of the TTMI 14 trial. J Am Coll Cardiol 1998; 31: 191A. 10.1016/S0735-1097(97)84535-4 Web of Science®Google Scholar 53 Ohman EM, Lincoff AM, Bode C, et al. Enhanced early reperfusion at 60 minutes with low-dose reteplase combined with full-dose abciximab in acute myocardial infarction: Preliminary results from the GUSTO-4 pilot (SPEED) dose-ranging trial. Circulation 1998; 98(Suppl. I): I–504. Google Scholar 54 Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation 2000; 101: 2788–2794. 10.1161/01.CIR.101.24.2788 PubMedGoogle Scholar 55 GUSTO-V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination therapy with reduced fibrinolytic therapy and glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial. Lancet 2001; 357: 1905–1914. 10.1016/S0140-6736(00)05059-5 CASPubMedWeb of Science®Google Scholar 56 Coller BS. Monitoring platelet GP IIb/IIIa antagonist therapy. Circulation 1997; 96: 3828–3832. CASPubMedWeb of Science®Google Scholar 57 Mark DB, Peterson ED. The health economics of acute coronary syndromes: Clinical and economic potential of GP IIb/IIIa antagonists. J Thromb Thrombol 1998; 5: 5155–5162. 10.1023/A:1008890302597 Google Scholar 58 Braunwald E, Amman E, Beasley JW, et al. for the Committee on the Management of Patients With Unstable Angina. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: Executive summary and recommendations. Circulation 2000; 102: 1193–1209. 10.1161/01.CIR.102.10.1193 CASPubMedWeb of Science®Google Scholar Citing Literature Volume15, Issue2April 2002Pages 121-129 ReferencesRelatedInformation